Announcements Trials

Browse Landscape

Phase

Status

Completed 9 Withdrawn 1 Unknown 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Lymphoma, Non-Hodgkin 2 Leukemia, Myeloid, Acute 2 Neoplasms, Plasma Cell 1 Multiple Myeloma 1 Lymphoma 1 Hodgkin Disease 1 Autologous Stem Cell Transplantation 1

Interventions

Cyclophosphamide 37 Etoposide 25 Vincristine 24 Cytarabine 21 Doxorubicin 19 Rituximab 17 Radiotherapy 17 Peripheral Blood Stem Cell Transplantation 16 Melphalan 16 Prednisolone 14 Methotrexate 14 Filgrastim 13 fludarabine phosphate 11 Prednisone 11 Dexamethasone 11 Carmustine 9 Bleomycin 9 pegylated granulocyte colony-stimulating factor 8 Cyclosporine 8 Busulfan 8 fludarabine 7 Ifosfamide 7 Cisplatin 7 sargramostim 6 Vinblastine 6 Mitoxantrone 6 Methylprednisolone 6 Gemcitabine 6 Chlorambucil 6 Antilymphocyte Serum 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Lymphoma × plerixafor × Clear all

NCT05510544 2023-03-13

Plerixafor for Poorly Mobilized Lymphoma

Peking University

Phase 4 Unknown

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡